CASC9

Summary

CASC9 (cancer susceptibility 9, HGNC:48906) is a long non-coding RNA gene on chromosome 8q21.13.

At a glance

• Gene type: non-coding (lncRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:48906
Approved symbol	CASC9
Name	cancer susceptibility 9
Location	8q21.13
Locus type	RNA, long non-coding
Status	Approved
Aliases	LINC00981, ESCCAL-1, linc-JPH1
Ensembl gene	ENSG00000249395
Ensembl biotype	lncRNA
Entrez	101805492
RNAcentral	URS000075EDE0 — lncRNA, 1471 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 15 — 14 lncRNA, 1 retained_intron

ENST00000504531, ENST00000521147, ENST00000522183, ENST00000523313, ENST00000654852, ENST00000669950, ENST00000670695, ENST00000675539, ENST00000675549, ENST00000675884, ENST00000675897, ENST00000676127, ENST00000676364, ENST00000795605, ENST00000795606

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000504531 — 3 exons

Exon	Start	End
ENSE00002034235	75278357	75278461
ENSE00002038106	75276987	75277090
ENSE00003902694	75223115	75224358

Expression profiles

Bgee: expression breadth ubiquitous, 126 present calls, max score 84.41.

Top tissues by expression

127 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	84.41	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	78.17	silver quality
mucosa of transverse colon	UBERON:0004991	77.03	gold quality
cerebellar vermis	UBERON:0004720	75.98	gold quality
colonic epithelium	UBERON:0000397	74.71	gold quality
placenta	UBERON:0001987	70.65	gold quality
rectum	UBERON:0001052	66.46	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	66.09	gold quality
bone marrow	UBERON:0002371	64.26	silver quality
hindlimb stylopod muscle	UBERON:0004252	63.72	gold quality
urinary bladder	UBERON:0001255	63.11	gold quality
skeletal muscle tissue	UBERON:0001134	62.67	gold quality
duodenum	UBERON:0002114	62.41	gold quality
transverse colon	UBERON:0001157	61.95	gold quality
ganglionic eminence	UBERON:0004023	61.34	gold quality
sural nerve	UBERON:0015488	60.43	silver quality
ventricular zone	UBERON:0003053	60.02	gold quality
thymus	UBERON:0002370	59.63	silver quality
kidney	UBERON:0002113	58.60	gold quality
adult mammalian kidney	UBERON:0000082	58.56	gold quality
muscle tissue	UBERON:0002385	57.94	gold quality
colon	UBERON:0001155	57.61	gold quality
liver	UBERON:0002107	56.90	gold quality
intestine	UBERON:0000160	56.44	gold quality
calcaneal tendon	UBERON:0003701	56.21	gold quality
leukocyte	CL:0000738	54.59	gold quality
islet of Langerhans	UBERON:0000006	54.38	gold quality
monocyte	CL:0000576	54.36	gold quality
pancreas	UBERON:0001264	53.10	gold quality
right lobe of liver	UBERON:0001114	52.31	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	2.20

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 40)

• The results indicated that CASC9 is significantly upregulated in ESCC tissues and may represent a new marker of poor prognosis and a potential therapeutic target for esophageal cancer intervention. (PMID:27431358)
• Data suggest that expression of long non-coding RNA (lncRNA)CASC9 correlated with aggressive pathological characteristics of gastric cancer (GC), it may serve as a potential oncogene to regulate proliferation, invasion, and chemoresistance of GC cells. (PMID:28146436)
• Oncogenic role of CASC9 in promoting the progression of NPC through regulating HIF1alpha, which imply that modulation of CASC9 expression may be a promising target in cancer therapy. (PMID:28398871)
• lncRNA CASC9 functions as an oncogene by negatively regulating PDCD4 expression through recruiting EZH2 and subsequently altering H3K27me3 level. Our study implicates lncRNA CASC9 as a valuable biomarker for ESCC diagnosis and prognosis. (PMID:28854977)
• high levels of CASC9.5 expression promote the proliferation, metastasis and metabolism of lung adenocarcinoma cells and might serve as a prognostic indicator. (PMID:29311567)
• Inhibition of CASC9 could suppress proliferation, migration, and invasion in esophageal squamous cell carcinoma . Aberrant CASC9 expression could modulate the expression levels of markers of Epithelial-Mesenchymal Transition . (PMID:29424900)
• Both CASC9 and LAMC2 depletion reduced the phosphorylation of FAK, PI3K, and Akt, which are downstream effectors of the integrin pathway. Moreover, the reduction in phosphorylation caused by CASC9 depletion was rescued by LAMC2 overexpression. (PMID:29511340)
• CASC9 is an oncogenic lncRNA. It is upregulated in hepatocellular carcinoma and associated with patient survival. Depletion of CASC9 decreases viability and proliferation. Depletion of CASC9 increases apoptosis of HCC cells. CASC9 interacts with HNRNPL. The CASC9:HNRNPL complex regulates the expression of AKT-signaling associated genes. The DNA damage signaling/response (DDR) is induced upon CASC9 and HNRNPL silencing. (PMID:29790588)
• CASC9:HNRNPL complex Is a clinically relevant viability-associated lncRNA/protein complex which affects AKT signaling and DNA damage sensing in hepatocellular carcinoma. (PMID:29790588)
• The study demonstrated the oncogenic role of CASC9 in drugresistant breast cancer by binding to EZH2 and regulating the MDR1 gene. Modulation of CASC9 expression may be a promising target in the therapy of breast cancer and drugresistant breast cancer. (PMID:30106089)
• our results concluded that CASC9 promotes STAT3 expression via sponging miR-519d, in return, STAT3 activate CASC9 transcription, forming a positive feedback loop of CASC9/miR-519d/STAT3. The novel finding provides a potential therapeutic target for glioma. (PMID:30270508)
• A novel undefined regulatory signaling pathway, namely the CASC9/miR-758-3p/LIN7A axis, involved in ovarian cancer progression. (PMID:30537154)
• Identification of oncogenic long noncoding RNAs CASC9 and LINC00152 in oral carcinoma through genome-wide comprehensive analysis. (PMID:30543527)
• Findings demonstrate that lncRNA CASC9 promotes OSCC progression through enhancing cell proliferation and suppressing autophagy-mediated cell apoptosis via the AKT/mTOR pathway. (PMID:30674868)
• Study revealed the overexpression and clinicopathological significance of CASC9 in lung squamous cell carcinoma (LUSC). Further data suggest that CASC9 serves as an oncogene in LUSC. (PMID:30896821)
• CASC9 enhances cervical cancer progression by promoting metastasis through the meditation of miR-215/TWIST2 signaling associated with TGF-beta expression (PMID:31178137)
• CASC9 is a promising prognostic predictor for patients with CRC and the CASC9-CPSF3-TGFbeta2 axis is a potential therapeutic target for CRC treatment. (PMID:31186036)
• Cancer susceptibility 9 long noncoding RNA (CASC9) is significantly overexpressed in head-and-neck squamous cell carcinoma (HNSCC) tumor tissues. Specificity of HNSCC detection by CASC9 is further improved by combination with tumor biomarker HOTAIR. Overexpression of CASC9 is found across other entities including bladder, liver, lung and stomach cancers and especially in squamous cell carcinoma (SCC) of the lung. (PMID:31412811)
• LncRNA CASC9 Suppressed the Apoptosis of Gastric Cancer Cells through Regulating BMI1. (PMID:31642035)
• CASC9 was positively correlated with GLUT-1 expression. (PMID:31669650)
• Control samples showed significantly lower CASC9 expression than hepatocellular carcinoma (HCC) tissue samples; the low CASC9 expression HCC group had a higher survival rate than the high CASC9 expression group, and the HCC group showed significantly increased expression of serum CASC9. CASC9 is expected to be a potential diagnostic and prognostic indicator of HCC. (PMID:31908394)
• Down-regulation of lncRNA CASC9 aggravates sepsis-induced acute lung injury by regulating miR-195-5p/PDK4 axis. (PMID:32221619)
• CASC9 Facilitates Cell Proliferation in Bladder Cancer by Regulating CBX2 Expression. (PMID:32570259)
• Long non-coding RNA CASC9 promotes tumor growth and metastasis via modulating FZD6/Wnt/beta-catenin signaling pathway in bladder cancer. (PMID:32677984)
• Long non-coding RNA CASC9 promotes the progression of retinoblastoma via interacting with miR-145-5p. (PMID:32772636)
• Long non-coding RNA ESCCAL-1 promotes esophageal squamous cell carcinoma by down regulating the negative regulator of APOBEC3G. (PMID:32905814)
• Oncogenic LncRNA CASC9 in Cancer Progression. (PMID:32940174)
• Long non-coding RNA CASC9 promotes gefitinib resistance in NSCLC by epigenetic repression of DUSP1. (PMID:33056982)
• lncRNA CASC9 sponges miR7583p to promote proliferation and EMT in bladder cancer by upregulating TGFbeta2. (PMID:33200222)
• CASC9 plays a role in salivary adenoid cystic carcinoma in vitro by upregulation of ACLY. (PMID:33345395)
• LncRNA CASC9 promotes proliferation, migration and inhibits apoptosis of hepatocellular carcinoma cells by down-regulating miR-424-5p. (PMID:33346094)
• Long non-coding RNA CASC9 promotes the progression and development of gastric cancer via regulating miR-370/EGFR axis. (PMID:33478874)
• LncRNACASC9 promotes proliferation, metastasis, and cell cycle inovarian carcinoma cells through cyclinG1/TP53/MMP7 signaling. (PMID:34595994)
• Long non-coding RNA CASC9 promotes tumor progression in oral squamous cell carcinoma by regulating microRNA-545-3p/laminin subunit gamma 2. (PMID:34612783)
• FOXO3-induced oncogenic lncRNA CASC9 enhances gefitinib resistance of non-small-cell lung cancer through feedback loop. (PMID:34619168)
• Long non-coding RNA (LncRNA) CASC9/microRNA(miR)-590-3p/sine oculis homeobox 1 (SIX1)/NF-kappaB axis promotes proliferation and migration in breast cancer. (PMID:34711117)
• Silencing LncRNA CASC9 inhibits proliferation and invasion of colorectal cancer cells by MiR-542-3p/ILK. (PMID:35427373)
• Abnormal expression of lncRNA CASC9 in pneumonia children with respiratory failure and its feasible value for the clinical diagnosis of patients. (PMID:35587261)
• LncRNA CASC9 activated by STAT3 promotes the invasion of breast cancer and the formation of lymphatic vessels by enhancing H3K27ac-activated SOX4. (PMID:35860965)
• CASC9 potentiates gemcitabine resistance in pancreatic cancer by reciprocally activating NRF2 and the NF-kappaB signaling pathway. (PMID:35913601)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.